GLP-1 prescribing among women with PCOS has risen seven-fold since 2021 — from 2.4% to 17.6% by 2025. Here's what the clinical trials actually show about weight loss and ovulation restoration, the critical on-label vs. off-label distinction, and why PCOS is increasingly understood as a metabolic condition rather than a purely reproductive one.
The largest 2026 study — 430,000+ patients across 30 trials — found bariatric surgery outperformed GLP-1 medications on every measured outcome. But researchers point to one major factor: up to 70% of GLP-1 patients discontinue within a year. Here's the full data, and why adherence may matter as much as the medication itself.
The shortage that made compounded semaglutide and tirzepatide widely available ended in 2025 — and the FDA has spent 2026 aggressively enforcing that shutdown, including 30 warning letters sent in a single day. Here's the current data on adverse events, enforcement actions, and what legal, affordable options still exist for patients.
The peptide therapeutics market reached roughly $164 billion in 2026 — but the bigger story is regulatory. In April 2026, the FDA removed 12 peptides, including CJC-1295, from its restricted Category 2 list. Here's what that actually means (and doesn't mean), plus the current market data, patient demand trends, and typical program costs.
An estimated 80 million American adults have obstructive sleep apnea — and roughly four in five have no idea. Untreated cases cost the US economy $150 billion annually. In December 2024, the FDA approved the first medication ever for OSA. Here's what the current data shows about prevalence, diagnosis gaps, and where drug treatment fits alongside CPAP.
Type 2 diabetes costs the United States $640 billion every year and affects 40.1 million Americans — with another 115 million on the path toward it. In 2026, GLP-1 receptor agonists are producing measurable diabetes remission in up to 18.3% of treated patients and are now first-line treatment under ADA guidelines. Here's what the full data picture looks like.
Stem cell therapy uses your body's own repair cells to reduce pain and heal damaged tissue without surgery. Board-certified interventional pain specialist Dr. Rosemary Daly, D.O., DABPM explains how it works, which conditions it treats, and what patients can expect from regenerative medicine at GoalBMI Wellness.
In pooled clinical trials, 43.9% of semaglutide patients reported nausea — but only 4.3% stopped treatment because of it. Here's what the trial data actually shows about GLP-1 side effects: discontinuation rates by cause, the lean mass question, gallbladder and thyroid risk, and why clinical supervision measurably changes who stays on treatment.
Only 36% of employers cover GLP-1 medications for weight loss — a number that hasn't moved since 2025. Medicare launched its first weight loss drug program in July 2026 at a $50 monthly copay, while four states cut Medicaid coverage entirely. Here's the complete 2026 coverage picture, plus the appeal statistic most patients never hear.
Tirzepatide became the world's best-selling drug in 2025 with $36.5 billion in combined Mounjaro and Zepbound sales. Clinical trials show 22.5% average weight loss the highest ever for a non-surgical treatment. Here are the most comprehensive tirzepatide statistics for 2026.
